Frank Hilberg

5.1k total citations · 1 hit paper
57 papers, 4.0k citations indexed

About

Frank Hilberg is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frank Hilberg has authored 57 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 18 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frank Hilberg's work include Angiogenesis and VEGF in Cancer (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Peptidase Inhibition and Analysis (7 papers). Frank Hilberg is often cited by papers focused on Angiogenesis and VEGF in Cancer (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Peptidase Inhibition and Analysis (7 papers). Frank Hilberg collaborates with scholars based in Austria, Germany and United States. Frank Hilberg's co-authors include Erwin F. Wagner, Gerald J. Roth, Adriano Aguzzi, Norma Howells, Ulrike Tontsch-Grunt, Pilar Garin‐Chesa, Armin Heckel, Wolfgang J. Rettig, Wolfram Ostertag and Jens Quant and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Frank Hilberg

56 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

2008 861 citations Frank Hilberg, Gerald J. Roth et al. Cancer Research profile →

Peers

Countries citing papers authored by Frank Hilberg

Since Specialization

Citations

This map shows the geographic impact of Frank Hilberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Hilberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Hilberg more than expected).

Fields of papers citing papers by Frank Hilberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Hilberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Hilberg. The network helps show where Frank Hilberg may publish in the future.

Co-authorship network of co-authors of Frank Hilberg

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Hilberg. A scholar is included among the top collaborators of Frank Hilberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Hilberg. Frank Hilberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance 2023 ·Molecular Cancer Therapeutics ·Miriam Marqués, (unknown), (unknown), Natalia del Pozo, Jaime Martínez de Villarreal, Norbert Schweifer, (unknown), Frank Hilberg, Francisco X. Real	3
2	Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models 2023 ·Frontiers in Oncology ·Niranjan Awasthi, Margaret A. Schwarz, (unknown), Changhua Zhang, Frank Hilberg, Roderich E. Schwarz	2
3	Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition 2022 ·Journal of Pharmacology and Experimental Therapeutics ·Irmgard Hofmann, Anke Baum, Marco H. Hofmann, Francesca Trapani, (unknown), (unknown), Martin Aichinger, Florian Ebner, (unknown), Norbert Schweifer, Martina M. Sykora, Erik Depla, (unknown), Andreas R. Gschwind, Norbert Kraut, Frank Hilberg, Klaus‐Peter Künkele	9
4	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist 2020 ·Molecular Cancer Therapeutics ·Juan Manuel García‐Martínez, Shirley Wang, (unknown), Andreas Wernitznig, Paolo Chetta, Catarina Pinto, Jason Ho, Darrin Dutcher, (unknown), Rachel Kroe‐Barrett, Joerg Rinnenthal, Craig Giragossian, (unknown), Iñigo Tirapu, Frank Hilberg, Norbert Kraut, Mark Pearson, (unknown)	23
5	Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib 2019 ·Journal of Biological Chemistry ·S. Terzyan, Tao Shen, Xuan Liu, Qingling Huang, Peng Teng, (unknown), Frank Hilberg, Jianfeng Cai, Blaine H. M. Mooers, Jie Wu	39
6	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer 2019 ·Journal of Experimental & Clinical Cancer Research ·(unknown), Ping Xu, Annabelle Chow, Shan Man, Frank Hilberg, Robert S. Kerbel	33
7	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo 2018 ·Clinical Cancer Research ·Viktória László, (unknown), Ildikó Kovács, (unknown), Mir Alireza Hoda, Thomas Klikovits, (unknown), András Czirók, Tamás Garay, (unknown), Thomas H. Helbich, (unknown), József Tóvári, Walter Klepetko, Christine Pirker, Michael Grusch, Walter Berger, Frank Hilberg, Balázs Hegedűs, Balázs Döme	25
8	P2.01-045 Nintedanib Improves Anti-Tumor Efficacy in Combination with Anti PD-1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition 2017 ·Journal of Thoracic Oncology ·Frank Hilberg, Markus Reschke, Marco H. Hofmann, Norbert Kraut	4
9	Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model 2015 ·Clinical Cancer Research ·Ruben Bill, Ernesta Fagiani, Adrian Zumsteg, Helena Antoniadis, (unknown), (unknown), Imke Albrecht, Frank Hilberg, Gerhard Christofori	27
10	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study) 2014 ·British Journal of Cancer ·Miguel Quintela-Fandiño, Ander Urruticoechea, Juan Antonio Guerra, (unknown), Antonio González-Martı́n, (unknown), (unknown), (unknown), Marta Gil-Martín, Raquel Bratos, M.J. Escudero, Soetkin Vlassak, Frank Hilberg, Rámón Colomer	29
11	Nintedanib: From Discovery to the Clinic 2014 ·Journal of Medicinal Chemistry ·Gerald J. Roth, Rudolf Binder, Florian Colbatzky, Claudia Dallinger, Rozsa Schlenker‐Herceg, Frank Hilberg, (unknown), R. Kaiser	259
12	Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas 2009 ·Radiotherapy and Oncology ·Daniel Zips, (unknown), Ala Yaromina, Annegret Dörfler, Wolfgang Eicheler, (unknown), Peter Geyer, Frank Hilberg, Michaël Baumann	20
13	BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy breakdown → 2008 ·Cancer Research ·Frank Hilberg, Gerald J. Roth, Martin Krššák, (unknown), Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin‐Chesa, Gerd Bader, Andreas Zoephel, Jens Quant, Armin Heckel, Wolfgang J. Rettig	861
14	CD44 Suppresses TLR-Mediated Inflammation 2008 ·The Journal of Immunology ·Hidetada Kawana, (unknown), Morihiro Higashi, Masaru Miyazaki, Frank Hilberg, Motoo Kitagawa, Kenichi Harigaya	77
15	C7-03: Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy 2007 ·Journal of Thoracic Oncology ·Frank Hilberg, (unknown)	16
16	Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse 2003 ·International Journal of Radiation Biology ·Michaël Baumann, Mechthild Krause, Daniel Zips, Wolfgang Eicheler, Annegret Dörfler, (unknown), Cordula Petersen, Kerstin Brüchner, Frank Hilberg	48
17	Expression of the fibroblast activation protein during mouse embryo development 2001 ·The International Journal of Developmental Biology ·(unknown), Pilar Garin‐Chesa, (unknown), Frank Hilberg, (unknown), U. Bamberger, Wolfgang J. Rettig, Andreas Schnapp	74
18	How Tumor Cells Make Use of CD44 1998 ·Cell adhesion and communications/Cell adhesion and communication/Cell adhesion & communication ·Peter Herrlich, Jonathan P. Sleeman, (unknown), Harald König, Larry S. Sherman, Frank Hilberg, Helmut Ponta	35
19	David Tudors Konzept des "elektrifizierten Klaviers" und seine Interpretation von John Cages "Variations II" (1961) 1996 ·Frank Hilberg	1
20	c-Jun is essential for normal mouse development and hepatogenesis 1993 ·Nature ·Frank Hilberg, Adriano Aguzzi, Norma Howells, Erwin F. Wagner	454

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact